Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars.
OBJECTIVE
The effect of pitavastatin on high-sensitivity C-reactive protein (hs-CRP) has not been reported, yet, in humans. We, therefore, investigated the effects of pitavastatin on lipid profiles and hs-CRP in Japanese subjects with hypercholesterolemia.


METHODS
The subjects were 178 Japanese with hypercholesterolemia, including 103 (58%) with type 2 diabetes. Pitavastatin (12 mg/day) was administered for 12 months. Serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), remnant-like particle cholesterol (RLP-C), triglycerides (TG) and hs-CRP levels were measured for 12 months.


RESULTS
Serum LDL-C and RLP-C levels were significantly decreased by 30.3% and 22.8%, respectively. Serum TG levels were decreased by 15.9% in subjects with basal TG levels above 150 mg/dl. Serum HDL-C levels were significantly increased. The administration of pitavastatin reduced serum hs-CRP levels by 34.8%. No serious adverse events were observed, including changes in glycosylated hemoglobin levels of diabetic patients.


CONCLUSIONS
These results suggest that pitavastatin significantly improves lipid profiles and reduces proinflammatory responses, without adverse effects, in Japanese subjects with hypercholesterolemia, including those with diabetes mellitus.
Koshiyama
Hiroyuki
H
Center for Diabetes & Endocrinology, The Tazuke Kofukai Foundation Medical Research Institute Kitano Hospital, Osaka, Japan. h-koshiyama@kitano-hp.or.jp
Taniguchi
Ataru
A
Tanaka
Kiyoshi
K
Kagimoto
Shinji
S
Fujioka
Yoshio
Y
Hirata
Kenichi
K
Nakamura
Yoshio
Y
Iwakura
Akane
A
Hara
Kyoko
K
Yamamoto
Taizo
T
Kuroe
Akira
A
Ohya
Michihiro
M
Fujimoto
Shimpei
S
Hamamoto
Yoshiyuki
Y
Honjo
Sachiko
S
Ikeda
Hiroki
H
Nabe
Koichiro
K
Tsuda
Kinsuke
K
Inagaki
Nobuya
N
Seino
Yutaka
Y
Kume
Noriaki
N
D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D007564:Japan; D008055:Lipids / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011804:Quinolines / Q000494:pharmacology*; D014280:Triglycerides / Q000378:metabolism
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011804:Quinolines; D014280:Triglycerides; D002097:C-Reactive Protein; C108475:pitavastatin